An update on menopausal hormone replacement therapy in women and cardiovascular disease

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 2, 2013, Pages 148-155

  Valdiviezo, Carolina ^a   Lawson, Shari ^a   Ouyang, Pamela ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Estrogen; Hormone therapy; Menopause

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; ISOFLAVONE; LASOFOXIFENE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PLACEBO; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; STROKE; TETRAHYDRONAPHTHALENES; TIME FACTORS; UNITED STATES; VENOUS THROMBOSIS; WOMEN'S HEALTH;

EID: 84874947596     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835ed58b     Document Type: Review

References (46)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321-333.
2. Nelson HD, Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157:104-113.
3. Marjoribanks J, Farquhar C, Roberts H, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7:CD004143.
4. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002; 53:550-557.
5. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009; 54:2366-2373.
6. Bittner V. Menopause age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol 2009; 54:2374-2375.
7. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008; 51:952-959.
8. Vaidya D, Becker DM, Bittner V, et al. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. Br Med J 2011; 343:d5170.
9. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105-1110.
10. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, causespecific mortality and total life expectancy. Epidemiology 2005; 16:556-562.
11. Falkeborn M, Schairer C, Naessen T, et al. Risk of myocardial infarction after oophorectomy and hysterectomy. J Clin Epidemiol 2000; 53:832-837.
12. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16:15-23.
13. Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012; 19:1081-1087.
14. Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12:259-285.
15. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47-63.
16. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-461.
17. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Commun Health 1989; 43:173-178.
18. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
19. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343:522-529.
20. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534.
21. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166:357-365.
22. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291:1701-1712.
23. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006; 15:35-44.
24. Hodis HN, Collins P, Mack WJ, et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15:217-228.
25. Salpeter SR, Walsh JM, Greyber E, et al. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006; 21:363-366.
26. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009; 119:922-930.
27. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronaryartery calcification. N Engl J Med 2007; 356:2591-2602.
28. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280:605-613.
29. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135:939-953.
30. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. J Am Med Assoc 2002; 288:2432-2440.
31. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349:535-545.
32. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Br Med J 2007; 335:239.
33. Toh S, Hernandez-Diaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010; 152:211-217.
34. Hodis HN, Mack WJ, Kono N, et al. Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. Stroke 2011; 42:3168-3175.
35. Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010; 122:1716-1724.
36. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J 2012; 345:e6409.
37. Kronos Early Estrogen Prevention Study (KEEPS) http://clinicaltrials.gov/ ct2/show/NCT00154180.
38. Early Versus Late Intervention Trial With Estradiol (ELITE) http://clinicaltrials. gov/ct2/show/NCT00114517.
39. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362:686-696.
40. Veerus P, Fischer K, Hakama M, et al. Results from a blind and a nonblind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial. BMC Med Res Methodol 2012; 12:44.
41. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 2008;112:1189-1192.
42. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19:257-271.
43. Estrogen and progestogen use in postmenopausal women. 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242-255.
44. Maclaran K, Stevenson JC. Primary prevention of cardiovascular disease with HRT. Womens Health (Lond Engl) 2012; 8:63-74.
45. Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011; 70:354-360.
46. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-845.